Kidney-brain crosstalk in the acute and chronic setting

Nature Reviews Nephrology

Volumn 11, Issue 12, 2015, Pages 707-719

  Lu, Renhua ^a   Kiernan, Matthew C ^b   Murray, Anne ^c   Rosner, Mitchell H ^d   Ronco, Claudio ^e  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM; SODIUM;

ACUTE DISEASE; ACUTE KIDNEY FAILURE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; COGNITIVE DEFECT; DIALYSIS ENCEPHALOPATHY; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; HEMODIALYSIS; HISTORY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MICROANGIOPATHY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROPATHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; WHITE MATTER LESION; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; BRAIN; BRAIN DISEASES; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; COMPLICATION; HUMAN; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; BRAIN; BRAIN DISEASES; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84948119021     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.131     Document Type: Review

References (154)

1. Coresh, J. et al. Prevalence of chronic kidney disease in the United States. JAMA 298,2038-2047 (2007).
2. Zhang, L. et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379, 815-822 (2012).
3. National Kidney Foundation. KIDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, S1-266 (2002).
4. Krishnan, A. V., Pussell, B. A., Kiernan, M. C. Neuromuscular disease in the dialysis patient: an update for the nephrologist. Semin. Dial. 22, 267-278 (2009).
5. Tilki, H. E., Akpolat, T., Coşkun, M., Stålberg, E. Clinical and electrophysiologic findings in dialysis patients. J. Electromyogr. Kinesiol. 19, 500-508 (2009).
6. Kurella, M. et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol. 16, 2127-2133 (2005).
7. Yaffe, K. et al. Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J. Am. Geriatr. Soc. 58, 338-345 (2010).
8. Seliger, S. L. et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J. Am. Soc. Nephrol. 15, 1904-1911 (2004).
9. Davey, A. et al. Decline in renal functioning is associated with longitudinal decline in global cognitive functioning, abstract reasoning and verbal memory. Nephrol. Dial. Transplant. 28, 1810-1819 (2013).
10. Buchman, A. S. et al. Kidney function is associated with the rate of cognitive decline in the elderly. Neurology 73, 920-927 (2009).
11. United States Renal Data System 2006 Annual Report. Morbidity & mortality. Neuroepidemiology: Incident & prevalent stroke [online] http://www.usrds.org/2006/pdf/06-morb-morte-06.pdf (2006).
12. Mehta, R. L. et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11, R31 (2007).
13. Lu, R. et al. Survey of acute kidney injury and related risk factors of mortality in hospitalized patients in a third-level urban hospital of Shanghai. Blood Purif. 38, 140-148 (2014).
14. Piccinni, P. et. al. Prospective multicentre study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol. 77, 1072-1083 (2011).
15. Akcay, A., Nguyen, Q., Edelstein, C. L. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009, 137072 (2009).
16. Ko, G. J., Rabb, H., Hassoun, H. T. Kidney-lung crosstalk in the critically ill patient. Blood Purif. 28, 75-83 (2009).
17. Benga, O., Huber, V. J. Brain water channel proteins in health and disease. Mol. Aspects Med. 33, 562-578 (2012).
18. Murray, A. M. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv. Chronic Kidney Dis. 15, 123-132 (2008).
19. Lee, M. et al. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 341, c4249 (2010).
20. Umemura, T. et al. Microalbuminuria is independently associated with deep or infratentorial brain microbleeds in hypertensive adults. Am. J. Hypertens. 25, 430-436 (2012).
21. Seliger, S. L., Longstreth, W. T. Jr. Lessons about brain vascular disease from another pulsating organ, the kidney. Stroke 39, 5-6 (2008).
22. Bukhari, F. J. et al. Effect of chronic kidney disease on the expression of thiamin and folic acid transporters. Nephrol. Dial. Transplant. 26, 2137-2144 (2011).
23. Wardlaw, J. M., Sandercock, P. A., Dennis, M. S., Starr, J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia Stroke 34, 806-812 (2003).
24. Weiner, D. E. et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am. J. Kidney Dis. 51, 212-223 (2008).
25. Debette, S. et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: The Framingham Offspring Study. Stroke 41, 600-606 (2010).
26. Martinez-Vea, A. et al. Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. Am. J. Kidney Dis. 47, 241-225 (2006).
27. Weiner, D. E. et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am. J. Kidney Dis. 53, 438-447 (2009).
28. Ikram, M. A. et al. Kidney function is related to cerebral small vessel disease. Stroke. 39, 55-61 (2008).
29. Wada, M. et al. Cerebral small vessel disease and chronic kidney disease (CKD): results of a crosssectional study in community-based Japanese elderly. J. Neurol. Sci. 272, 36-42 (2008).
30. Abramson, J. et al. Chronic kidney disease, anaemia, and incident stroke in a middle-aged, community-based population: The aric study. Kidney Int. 64, 610-615 (2003).
31. Ovbiagele, B. et al. Indices of kidney dysfunction and discharge outcomes in hospitalized stroke patients without known renal disease. Cerebrovasc. Dis. 28, 582-588 (2009).
32. Kumai, Y. et al. Proteinuria and clinical outcomes after ischemic stroke. Neurology 78, 1909-1915 (2012).
33. Chou, C. C. et al. Adults with late stage 3 chronic kidney disease are at high risk for prevalent silent brain infarction. a population-based study. Stroke 42, 2120-2125 (2011).
34. Shima, H. et al. Decreased kidney function is a significant factor associated with silent cerebral infarction and periventricular hyperintensities. Kidney Blood Press. Res. 34, 430-438 (2011).
35. Kobayashi, M. et al. Relationship between silent brain infarction and chronic kidney disease. Nephrol. Dial. Transplant. 24, 201-207 (2009).
36. Seliger. S. L. et al. Cystatin C and subclinical brain infarction. J. Am. Soc. Nephrol. 16, 3721-3727 (2005).
37. Kobayashi, M. et al. Silent brain infarction and rapid decline of kidney function in patients with CKD: a prospective cohort study. Am. J. Kidney Dis. 56, 468-476 (2010).
38. Ovbiagele, B. et al. Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral haemorrhage. Stroke 44, 2409-2413 (2013).
39. Seliger, S. L. et al. Risk factors for incident stroke among patients with end-stage renal disease. J. Am. Soc. Nephrol. 14, 2623-2631 (2003).
40. Wetmore, J. B. et al. Atrial fibrillation and risk of stroke in dialysis patients. Ann. Epidemiol. 23, 112-118 (2013).
41. Murray, A. M., Seliger, S., Lakshminarayan, K., Herzog, C. A., Solid, C. A. Incidence of stroke before and after dialysis initiation in older patients. J. Am. Soc. Nephrol. 24, 1166-1173 (2013).
42. Chen, Y. et al. 24-h residual urine volume at haemodialysis initiation: a possible predictor for acute ischemic stroke incurrence in haemodialysis patients. Clin. Neurol. Neurosurg. 115, 557-561 (2013).
43. Anan, F. et al. Hyperhomocysteinaemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing haemodialysis. Metabolism 55, 656-661 (2006).
44. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 288, 2015-2022 (2002).
45. Lee, M., Hong, K. S., Chang, S. C., Saver, J. L. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 41, 1205-1212 (2010).
46. Martin-Malo, A. et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol. Dial. Transplant. 27, 2465-2471 (2011).
47. Kshirsagar, A. V. et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in haemodialysis patients. PLoS ONE 8, e78930 (2013).
48. Wang, H. H. et al. Risk of stroke in long-term dialysis patients compared with the general population. Am. J. Kidney Dis. 63, 604-611 (2014).
49. Foley, R. N., Gilbertson, D. T., Murray, T., Collins, A.J. Long interdialytic interval and mortality among patients receiving haemodialysis. N. Engl. J. Med. 365, 1099-1107 (2011).
50. Herzog, C. A. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 80, 572-586 (2011).
51. Power, A., Chan, K., Singh, S. K., Taube, D., Duncan, N. Appraising stroke risk in maintenance haemodialysis patients: a large single-centre cohort study. Am. J. Kidney Dis. 59, 249-257 (2012).
52. Toyoda, K. et al. Stroke in patients on maintenance haemodialysis: a 22-year single-centre study. Am. J. Kidney Dis. 45, 1058-1066 (2005).
53. Iseki, K. Stroke feature and management in dialysis patients. Contrib. Nephrol. 179, 100-109 (2013).
54. Strippoli, G. F. et al. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in haemodialysis patients: the clinical evaluation of the dose of erythropoietins (C. E. DOSE) trial protocol. Trials 9, 70 (2010).
55. Davies, S., Lally, F., Satchithananda, D., Kadam, U., Roffe, C. Extending the role of peritoneal dialysis: can we win hearts and minds Nephrol. Dial. Transplant. 29, 1648-1654 (2014).
56. Godino Mdel, C. et al. Amelioration of ischemic brain damage by peritoneal dialysis. J. Clin. Invest. 123, 4359-4363 (2013).
57. Kurella, M., Yaffe, K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int. 79, 14-22 (2011).
58. Murea, M. et al. Structural and functional assessment of the brain in European Americans with mild-to-moderate kidney disease: Diabetes Heart Study-MIND. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfv030.
59. Lee, J. J. et al. Impaired frontal executive function and predialytic chronic kidney disease. J. Am. Geriatr. Soc. 59, 1628-1635 (2011).
60. Miwa, K. et al. Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. Neurology 82, 1051-1057 (2014).
61. Brouns, R., De Deyn, P. P. Neurological complications in renal failure: a review. Clin. Neurol. Neurosurg. 107, 1-16 (2004).
62. Kurella, M., Luan, J., Yaffe, K., Chertow, G. M. Validation of the Kidney Disease Quality of Life (KDQOL) Cognitive Function subscale. Kidney Int. 66, 2361-2367 (2004).
63. Folstein, M. F., Folstein, S. E., McHugh, P. R. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198 (1975).
64. Teng, E. L., Chui, H. C. The Modified Mini-Mental State (3MS) examination. J. Clin. Psychiatry. 48, 314-318 (1987).
65. Callahan, C. M. et al. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med. Care 40, 771-781 (2002).
66. Tariq, S. H. et al. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder-a pilot study. Am. J. Geriatr. Psychiatry. 14, 900-910 (2006).
67. Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695-699 (2005).
68. Holsinger, T., Deveau, J., Boustani, M., Williams, J. W. Jr. Does this patient have dementia JAMA 297, 2391-2404 (2007).
69. Koga, H. et al. Cognitive consequences of multiple lacunes and leukoaraiosis as vascular cognitive impairment in community-dwelling elderly individuals. J. Stroke Cerebrovasc. Dis. 18, 32-37 (2009).
70. Kurella, M., Yaffe, K., Shlipak, M. G, Wenger, N. K., Chertow, G. M. Chronic kidney disease and cognitive impairment in menopausal women. Am. J. Kidney Dis. 45, 66-76 (2005).
71. Umemura, T. et al. Association of chronic kidney disease and cerebral small vessel disease with cognitive impairment in elderly patients with type 2 diabetes. Dement. Geriatr. Cogn. Dis. Extra 3, 212-222 (2013).
72. Kurella Tamura, M. et al. Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study. Clin. J. Am. Soc. Nephrol. 6, 248-256 (2011).
73. Perna, A. F. et al. Hyperhomocysteinaemia in uraemia-a red flag in a disrupted circuit. Semin. Dial. 22, 351-356 (2009).
74. Fassbender, K. et al. Homocysteine in cerebral macroangiography and microangiopathy. Lancet 353, 1586-1587 (1999).
75. Wright, C. B. et al. Total homocysteine is associated with white matter hyperintensity volume: The Northern Manhattan Study. Stroke 36, 1207-1211 (2005).
76. Lipton, S. A. et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-Daspartate receptor. Proc. Natl. Acad. Sci. USA 94, 5923-5928 (1997).
77. Bernstein, H. G., Bogerts, B., Keilhoff, G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res. 78, 69-86 (2005).
78. Fujisaki, K. et al. Cerebral oxidative stress induces spatial working memory dysfunction in uraemic mice: neuroprotective effect of tempol. Nephrol. Dial. Transplant. 29, 529-538 (2014).
79. Hailpern, S. M., Melamed, M. L., Cohen, H. W., Hostetter, T. H. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J. Am. Soc. Nephrol. 18, 2205-2213 (2007).
80. Sajjad, I., Grodstein, F., Kang, J. H., Curhan, G. C., Lin, J. Kidney dysfunction and cognitive decline in women. Clin. J. Am. Soc. Nephrol. 7, 437-443 (2012).
81. Chronic Kidney Disease Prognosis Consortium et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073-2081 (2010).
82. Kurella, M., Mapes, D. L., Port, F. K., Chertow, G.M. Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrol. Dial. Transplant. 21, 2543-2548 (2006).
83. Drew, D. A. et al. FGF-23 and cognitive performance in haemodialysis patients. Haemodial. Int. 18, 78-86 (2014).
84. Shaffi, K. et al. Low 25-hydroxyvitamin D levels and cognitive impairment in haemodialysis patients. Clin. J. Am. Soc. Nephrol. 8, 979-986 (2013).
85. Grimm, G., et al. Improvement of brain function in haemodialysis patients treated with erythropoietin. Kidney Int. 38, 480-486 (1990).
86. Kurella Tamura, M. et al. Effect of more frequent haemodialysis on cognitive function in the Frequent Haemodialysis Network trials. Am. J. Kidney Dis. 61, 228-237 (2013).
87. Murray, A. M. et al. Cognitive impairment in haemodialysis patients is common. Neurology. 67, 216-223 (2006).
88. Jassal, S. V., Devins, G. M., Chan, C. T., Bozanovic, R., Rourke, S. Improvements in cognition in patients converting from thrice weekly haemodialysis to nocturnal haemodialysis: a longitudinal pilot study. Kidney Int. 70, 956-962 (2006).
89. Evans, J. D., Wagner, C. D., Welch, J. L. Cognitive status in haemodialysis as a function of fluid adherence. Ren. Fail. 26, 575-581 (2004).
90. Liu, S., Quarles, L. D. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 18, 1637-1647 (2007).
91. Madero, M., Gul, A., Sarnak, M. J. Cognitive function in chronic kidney disease. Semin. Dial. 21, 29-37 (2008).
92. Paramjit, K. et al. Cognitive impairment in peritoneal dialysis patients. Am. J. Kidney Dis. 57, 612-620 (2011).
93. Sehgal, A. R., Grey, S. F., DeOreo, P. B., Whitehouse, P.J. Prevalence, recognition, and implications of mental impairment among haemodialysis patients. Am. J. Kidney Dis. 30, 41-49 (1997).
94. Claesson, L., Linden, T., Skoog, I., Blomstrand, C. Cognitive impairment after stroke-impact on activities of daily living and costs of care for elderly people. The Göteborg 70+ Stroke Study. Cerebrovasc. Dis. 19, 102-109 (2005).
95. Collins, A. J. et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am. J. Kidney Dis. 45, A5-A7, S1-S280 (2005).
96. Wolfgram, D., Szabo, A., Murray, A. M., Whittle, J. Risk of dementia in peritoneal dialysis patients compared with hemodialysis patients. Perit. Dial. Int. 35, 189-198 (2015).
97. Teschan, P. E. Electroencephalographic and other neurophysiological abnormalities in uraemia. Kidney Int. Suppl. 2, 210-216 (1975).
98. Haemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am. J. Kidney Dis. 48, S2-90 (2006).
99. Peritoneal Dialysis Adequacy 2006 Work Group. Clinical practice guidelines for peritoneal dialysis adequacy. Am. J. Kidney Dis. 48, S98-129 (2006).
100. Murray, A. M. et al. Acute variation in cognitive function in haemodialysis patients: a cohort study with repeated measures. Am. J. Kidney Dis. 50, 270-278 (2007).
101. Gottlieb, D., Mildworf, B., Rubinger, D., Melamed, E. The regional cerebral blood flow in patients under chronic haemodialytic treatment. J. Cereb. Blood Flow Metab. 7, 659-661 (1987).
102. Postiglione, A. et al. Changes in middle cerebral artery blood velocity in uremic patients after haemodialysis. Stroke 22, 1508-1511 (1991).
103. Hata, R. et al. Effects of hemodialysis on cerebral circulation evaluated by transcranial Doppler ultrasonography. Stroke 25, 408-412 (1994).
104. Ishida, I. et al. Hemodialysis causes severe orthostatic reduction in cerebral blood flow velocity in diabetic patients. Am. J. Kidney Dis. 34, 1096-1104 (1999).
105. Dogukan, A. et al. The effect of strict volume control on cognitive functions in chronic haemodialysis patients. Ren. Fail. 31, 641-646 (2009).
106. Freyberger, H., Bauditz, W. Psychosyndrome and somatic reactions in chronic kidney patients undergoing hemodialysis [German]. Verh. Dtsch. Ges. Inn. Med. 75, 971-977 (1969).
107. Rozas, V. V., Port, F. K., Easterling, R. E. An outbreak of dialysis dementia due to aluminium in the dialysate. J. Dial. 2, 459-470 (1978).
108. Jack, R., Rabin, P. L., McKinney, T. D. Dialysis encephalopathy: a review. Int. J. Psychiatry Med. 13, 309-326 (1984).
109. Kennedy, A. C., Linton, A. L., Eaton, J. C. Urea levels in cerebrospinal fluid after haemodialysis. Lancet 1, 410-411 (1962).
110. Rodrigo, F. et al. Osmolality changes during haemodialysis. Natural history, clinical correlations, and influence of dialysate glucose and intravenous mannitol. Ann. Intern. Med. 86, 554-561 (1977).
111. Chen, C. L. et al. A preliminary report of brain edema in patients with uremia at first hemodialysis: evaluation by diffusion-weighted MR Imaging. Am. J. Neuroradiol. 28, 68-71 (2007).
112. Arieff, A. I., Massry, S. G., Barrientos, A., Kleeman, C. R. Brain water and electrolyte metabolism in uraemia: effects of slow and rapid hemodialysis. Kidney Int. 4, 177-187 (1973).
113. Trinh-Trang-Tan, M. M., Cartron, J. P., Bankir, L. Molecular basis for the dialysis disequilibrium syndrome: altered aquaporin and urea transporter expression in the brain. Nephrol. Dial. Transplant. 20, 1984-1988 (2005).
114. Griva, K. et al. Acute neuropsychological changes in hemodialysis and peritoneal dialysis patients. Health Psychol. 22, 570-578 (2003).
115. Williams, M. A., Sklar, A. H., Burright, R. G., Donovick, P. J. Temporal effects of dialysis on cognitive functioning in patients with ESRD. Am. J. Kidney Dis. 43, 705-711 (2004).
116. Lewis, E. G., O'Neill, W. M., Dustman, R. E., Beck, E.C. Temporal effects of hemodialysis on measures of neural efficiency. Kidney Int. 17, 357-363 (1980).
117. Pliskin, N. H., Yurk, H. M., Ho, L.T ., Umans, J. G. Neurocognitive function in chronic chronic haemodialysis patients. Kidney Int. 49, 1435-1440 (1996).
118. English, A., Savage, R. D., Britton, P. G., Ward, M. K., Kerr, D. N. Intellectual impairment in chronic renal failure. BMJ 1, 888-890 (1978).
119. Ratner, D. P., Adams, K. M., Levin, N. W., Rourke, B. P. Effects of haemodialysis on the cognitive and sensory-motor functioning of the adult chronic haemodialysis patient. J. Behav. Med. 6, 291-311 (1983).
120. Smirnov, A. V. et al. Quality of life and cognitive functions in patients with end-stage renal failure on haemodialysis using a succinate-containing dialysing solution [Russian]. Ter. Arkh. 86, 11-17 (2014).
121. Drew, D. A. et al. Cognitive performance before and during haemodialysis: a randomized cross-over trial. Nephron Clin. Pract. 124, 151-158 (2013).
122. van Eijk, M. M. et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 376, 1829-1837 (2010).
123. Bergen, D. C., Ristanovic, R., Gorelick, P. B., Kathpalia, S. Seizures and renal failures. Int. J. Artif. Organs 17, 247-251 (1994).
124. Duranton, F. et al. Normal and pathologic concentrations of uraemic toxins. J. Am. Soc. Nephrol. 23, 1258-1270 (2012).
125. De Deyn, P. P., Vanholder, R., Eloot, S., Glorieux, G. Guanidino compounds as uremic (neuro) toxins. Semin. Dial. 22, 340-345 (2009).
126. Kielstein, J. T. et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37, 2024-2029 (2006).
127. De Deyn, P. P., D'Hooge, R., Van Bogaert, P. P., Marescau, B. Endogenous guanidino compounds as uraemic neurotoxins. Kidney Int. 78, S77-S83 (2001).
128. Liu, M. et al. Acute kidney injury leads to inflammation and functional changes in the brain. J. Am. Soc. Nephrol. 19, 1360-1370 (2008).
129. Aguilera, A., Sánchez-Tomero, J. A., Selgas, R. Brain activation in uraemic anorexia. J. Ren. Nutr. 17, 57-61 (2007).
130. Aguilera, A. et al. Eating behaviour disorders in uremia: a question of balance in appetite regulation. Semin. Dial. 17, 44-52 (2004).
131. Smogorzewski, M. et al. Chronic parathyroid hormone excess in vivo increases resting levels of cytosolic calcium in brain synaptosomes: studies in the presence and absence of chronic renal failure. J. Am. Soc. Nephrol. 1, 1162-1168 (1991).
132. Smogorzewski, M. J. Central nervous dysfunction in uraemia. Am. J. Kidney Dis. 38, s122-128 (2001).
133. Griva, K. et al. Cognitive functioning pre-to post-kidney transplantation-a prospective study. Nephrol. Dial. Transplant. 21, 275-273 (2006).
134. Harciarek, M. et al. Cognitive performance before and after kidney transplantation: a prospective controlled study of adequately dialysed patients with end-stage renal disease. J. Int. Neuropsychol. Soc. 15, 684-694 (2009).
135. Radić, J. et al. Kidney transplantation improves cognitive and psychomotor functions in adult haemodialysis patients. Am. J. Nephrol. 34, 399-406 (2011).
136. Yap, S. C., Lee, H. T. Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. Anaesthesiology 116, 1139-1148 (2012).
137. Edelstein, C. L., Schrier, R. W. in Diseases of the Kidney and Urinary Tract 8th edn Vol. 2 Ch. 36 (ed. Schrier, R. W.) 930-961 (Lippincott Williams & Wilkins, 2007).
138. Li, X., Hassoun, H. T., Santora, R., Rabb, H. Organ crosstalk: the role of the kidney. Curr. Opin. Crit. Care 15, 481-487 (2009).
139. Shrestha, R., Millington, O., Brewer, J., Bushell, T. Is central nervous system an immune-privileged site Kathmandu Univ. Med. J. 11, 102-107 (2013).
140. Ramesh, G., MacLean, A. G., Philipp, M. T. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. http://dx.doi.org/10.1155/2013/480739
141. Adachi, N. et al. Uraemia suppresses central dopaminergic metabolism and impairs motor activity in rats. Intensive Care Med. 27, 1655-1660 (2001).
142. Salama, M. et al. Up-regulation of TLR-4 in the brain after ischemic kidney-induced encephalopathy in the rat CNS. Neurol. Disord. Drug Targets 12, 583-586 (2013).
143. White, L. E., Hassoun, H. T. Inflammatory mechanisms of organ crosstalk during ischemic acute kidney injury. Int. J. Nephrol. http://dx.doi.org/10.4061/2012/505197
144. Wang, Y., Ge, P., Zhu, Y. TLR2 and TLR4 in the brain injury caused by cerebral ischemia and reperfusion. Mediators Inflamm. 124, 614 (2013).
145. Umehara, H. et al. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol. Cell Biol. 79, 298-302 (2001).
146. Furuichi, K. et al. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J. Immunol. http://dx.doi.org/10.1155/2013/124614
147. Cockwell, P., Chakravorty, S. J., Girdlestone, J. and Savage, C. O. Fractalkine expression in human renal inflammation. J. Pathol. 196, 85-90 (2002).
148. Lu, L. H. et al. Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. Pharmacol. Exp. Ther. 324, 111-117 (2008).
149. Frangogiannis, N. G. Chemokines in ischemia and reperfusion. Thromb. Haemost. 97, 738-747 (2007).
150. Sonneville, R. et al. Understanding brain dysfunction in sepsis. Ann. Intensive Care 3, 3-15 (2013).
151. Bedford, J. J., Leader, J. P., Walker, R. J. Aquaporin expression in normal human kidney and in renal disease. J. Am. Soc. Nephrol. 14, 2581-2587 (2003).
152. Ribeiro Mde, C., Hirt, L., Bogousslavsky, J., Regli, L., Badaut, J. Time course of aquaporin expression after transient focal cerebral ischemia in mice. J. Neurosci. Res. 15, 1231-1240 (2006).
153. Gu, Y., Dee, C. M., Shen, J. Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability. Front. Biosci. (Schol. Ed.) 3, 1216-1231 (2011).
154. Haorah, J. et al. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J. Neurochem. 101, 566-576 (2007).